Diabetic endothelial dysfunction: the role of poly(ADP-ribose) polymerase activation

Area of Science:

• Biomedical Science
• Endocrinology
• Vascular Biology

Background:

• Diabetic patients often develop microvascular and macrovascular complications.
• Endothelial dysfunction is an early hallmark of diabetic vascular damage.
• Poly(ADP-ribose) polymerase (PARP) activation is implicated in diabetes pathogenesis.

Purpose of the Study:

• To investigate the role of PARP activation in diabetic endothelial dysfunction.
• To evaluate the therapeutic potential of PARP inhibition in preserving vascular function in diabetes.

Main Methods:

• Induction of hyperglycemia and islet cell destruction in mice using streptozotocin.
• Assessment of endothelial function, oxidant production, and DNA strand breakage.
• Treatment with a novel PARP inhibitor post-hyperglycemia induction.
• In vitro studies using endothelial cells incubated in high glucose.

Main Results:

• Hyperglycemia induced DNA strand breakage, PARP activation, and loss of endothelium-dependent vasodilation in mice.
• PARP inhibition preserved vascular responsiveness despite persistent hyperglycemia.
• High glucose in vitro caused oxidative stress, DNA damage, and PARP activation in endothelial cells.
• PARP deficiency reduced nuclear factor-kappaB activation in endothelial cells.

Conclusions:

• PARP activation is a key mediator of endothelial dysfunction in diabetes.
• PARP inhibition represents a promising therapeutic strategy for diabetic vascular complications.
• Targeting PARP may offer a novel approach to treating diabetic endothelial dysfunction.